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Background: Dose equivalence of antidepressants is critically important for clinical practice and for
research. There are several methods to deﬁne and calculate dose equivalence but for antidepressants,
only daily deﬁned dose and consensus methods have been applied to date. The purpose of the present
study is to examine dose equivalence of antidepressants by a less arbitrary and more systematic method.
Methods: We used data from all randomized, double-blind, ﬂexible-dose trials comparing ﬂuoxetine or
paroxetine as standard drugs with any other active antidepressants as monotherapy in the acute phase
treatment of unipolar depression. We calculated the ratio of the mean doses for each study and weighted
it by the total sample size to ﬁnd the weighted mean ratio for each drug, which was then used to deﬁne
the drug's dosage equivalent to ﬂuoxetine 40 mg/d.
Results: We included 83 studies (14 131 participants). In the primary analysis, ﬂuoxetine 40 mg/day was
equivalent to paroxetine dosage of 34.0 mg/day, agomelatine 53.2 mg/day, amitriptyline, 122.3 mg/day,
bupropion 348.5 mg/day, clomipramine 116.1 mg/day, desipramine 196.3 mg/day, dothiepin 154.8 mg/
day, doxepin 140.1 mg/day, escitalopram 18.0 mg/day, ﬂuvoxamine 143.3 mg/day, imipramine 137.2 mg/
day, lofepramine 250.2 mg/day, maprotiline 118.0 mg/day, mianserin, 101.1 mg/day, mirtazapine 50.9 mg/
day, moclobemide 575.2 mg/day, nefazodone 535.2 mg/day, nortriptyline 100.9 mg/day, reboxetine
11.5 mg/day, sertraline 98.5 mg/day, trazodone 401.4 mg/day, and venlafaxine 149.4 mg/day. Sensitivity
analyses corroborated the results except for doxepin.
Limitations: The number of studies for some drugs was small. The current method assumes dose
response relationship of antidepressants.
Conclusions: Our ﬁndings can be useful for clinicians when they switch antidepressants and for
researchers when they compare various antidepressants in their research.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Pharmacotherapy with antidepressants is the mainstay in the
treatment of major depressive disorder. Although many types of
antidepressants are currently available, evidence-based dose
equivalency among them which takes relative efﬁcacy into con-
sideration is unknown.
Dose equivalence is critically important for clinical practice and for
research. First, when clinicians change antidepressant, they need to
know approximate dose equivalents to facilitate the transition. Second,
dose equivalence is also relevant for pharmacoepidemiological studies
for fair and accurate comparison of antidepressants to check poten-
tial over- or under-prescription. In addition, in trials comparing
antidepressants, and in their meta-analyses, setting comparable
dosages is necessary to facilitate the interpretation (Hansen et al.,
2009).
There are several methods to deﬁne and calculate dose equiva-
lence. Patel et al. (2013) conducted a systematic review of available
methods that compare dose equivalence of antipsychotics. The
representative methods include the following:
i) Original method conducted by Davis (1974). He employed data
from double-blind ﬂexible-dose trials comparing chlorpromazine
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with other antipsychotics, and then calculated the mean dose of
each antipsychotic drug that was as effective as the standard
comparator chlorpromazine 100 mg/day.
ii) Minimum effective dose method. The lowest dose signiﬁcantly
superior to placebo of equally efﬁcacious drugs based on
placebo controlled ﬁxed dose trials was considered to be
equivalent (Leucht et al., 2014; Woods, 2003).
iii) Near-effective maximum dose method. The threshold dose
eliciting clinical response with the least adverse proﬁle was
considered equivalent, based on the dose-response curves
from data of ﬁxed dose randomized placebo-controlled studies
(Davis and Chen, 2004).
iv) Daily deﬁned dose (DDD) (World Health Organization, 2014).
DDD is the assumed average maintenance dose per day
calculated from the dosage recommendations in each drug's
product information. This is the ofﬁcial standard of reference
for WHO member states.
v) Expert consensus methods (Buckley, 2005; Gardner et al.,
2010; Kane et al., 2003; Simpson et al., 2006).
Each method has its strengths and limitations, and no gold
standard method exists. In the case of antidepressants, to the best
of our knowledge, dose equivalence is provided only as DDD and by
the consensus methods (Inagaki and Inada, 2006; Inagaki et al., 1999).
DDD is often deﬁned as a compromise among available information
from various countries and does not provide any information about
efﬁcacy of each drug (World Health Organization, 2014). Ali (1998)
and Fava and Davidson (1996) studies showed a table of equivalent
dose of antidepressants, but no further detail about how they
calculated and obtained these values were provided.
The minimum effective dose method is limited by availability of
placebo-controlled dose-ﬁnding studies and, when such is avail-
able, by their design if the trial had set the true minimum effective
dose and if the trial was powered enough to detect such differ-
ence. Near-effective maximum dose design, while theoretically
attractive, is even more severely affected by availability of appro-
priate studies in which we can draw dose-response curves. In the
current study we therefore aimed to examine antidepressant dose
equivalence applying the original method by Davis (1974). This
method used data from double-blind ﬂexible-dose studies, in
which physicians adjust dosages to optimize the clinical response
without knowing the prescription. It may be assumed that the
resulting average doses represent the optimum mean doses for
each drug so this can be used to estimate the clinically equivalent
doses between drugs.
2. Materials and methods
As standard drugs, we chose ﬂuoxetine and paroxetine, which are
the ﬁrst and second most often trialed drugs in the recent years
(Cipriani et al., 2009). Both are representative selective serotonin
reuptake inhibitors (SSRI) with similar side effect proﬁles and recom-
mended dose ranges. The current study is an updated derivative work
from our two recent Cochrane reviews for ﬂuoxetine (Magni et al.,
2013) and paroxetine (Purgato et al., 2014). We merged the results for
ﬂuoxetine and paroxetine by converting paroxetine mean dosage of
each study into ﬂuoxetine mean dosage by the calculation below. The
validity of the decision to merge the two datasets was examined in a
sensitivity analysis.
2.1. Types of studies
We retrieved all randomized, double-blind, ﬂexible-dose
trials comparing ﬂuoxetine or paroxetine with any other active
antidepressants as monotherapy in the acute phase treatment of
unipolar depression.
2.2. Types of participants
The reviews included participants 18 years or older, of both sexes,
with a primary diagnosis of unipolar major depression according to
standardized criteria, DSM-III, DSM-III-R, DSM-IV (American
Psychiatric Association, 2000), ICD-10 (World Health Organization,
1992), Feighner criteria (Feighner et al., 1972) or Research Diagnostic
Criteria (Spitzer et al., 1978). Studies using ICD- 9 were excluded
because it only lists disease names but do not have diagnostic
criteria.
We excluded studies that focused on children and adolescents only,
or on elderly patients (mean age4¼65 years), because their indicated
dosages and/or efﬁcacy may be different from the case of adults.
We included participants with some subtypes of depression,
such as chronic, with catatonic features, with melancholic features,
with atypical features, with postpartum onset, and with a seasonal
pattern. We included studies in which up to 20% of participants
presented with depressive episodes in bipolar affective disorder
and participants with a concurrent secondary diagnosis of another
psychiatric disorder. We excluded participants with a concurrent
primary diagnosis of another psychiatric disorder and participants
with a serious concomitant medical illness.
2.3. Interventions
The standard intervention drugs in this study were ﬂuoxetine or
paroxetine as ﬂexible dose monotherapy. We concentrated on the
acute phase treatment, deﬁned as 4–16 weeks of treatment, with
the preferred endpoint at 8 weeks. When 8-week data were not
available, we used outcomes closest to 8 weeks within the 4–16-
week range. We excluded trials in which ﬂuoxetine or paroxetine
was compared only to placebo or another class of psychopharma-
cological agents such as anxiolytics, anticonvulsants, antipsychotics
or mood stabilizers, and trials in which ﬂuoxetine or paroxetine was
used as an augmentation strategy.
2.4. Comparators
Comparator drugs included conventional antidepressive agents
as follows:
1. Tricyclics (TCAs); Amitriptyline, Clomipramine, Desipramine,
Dothiepin/Dosulepin, Doxepin, Imipramine, Lofepramine, Tri-
mipramine, Nomifensine, and Nortriptyline
2. Heterocyclics; Maprotiline, and Mianserin
3. SSRIs; Citalopram, Escitalopram, Fluvoxamine, Paroxetine, and
Sertraline
4. SNRIs; Duloxetine, Milnacipran, and Venlafaxine
5. MAOIs or newer ADs; Agomelatine, Mirtazapine, Moclobemide,
Phenelzine, and Reboxetine
6. Other conventional antidepressive drugs; Amineptine, Amisul-
pride, Bupropion, Pramipexole, Nefazodone, Tianepine, and
Trazodone
No restrictions on dose, frequency or intensity were applied in
the ﬁrst round of the study selection. From this source dataset, we
selected all double-blind, ﬂexible-dose studies, and we included
studies whose ﬂexible dose range were within or included either
the lower or the upper limit of the target dose range of each drug,
set a priori as follows:
Fluoxetine 10–80 mg/day, Paroxetine 12.5–75 mg/day, Ago-
melatine 25–50 mg/day, Amisulpride 50–300 mg/day, Amitrip-
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tyline 75–300 mg/day, Bupropion 150–450 mg/day, Citalopram
20–40 mg/day, Clomipramine 25–250 mg/day, Desipramine 100–
300 mg/day, Doxepin 25–300 mg/day, Duloxetine 40–120 mg/
day, Escitalopram 10–20 mg/day, Fluvoxamine 50–300 mg/day,
Imipramine 75–300mg/day, Lofepramine 140–210mg/day,
Maprotiline 25–225mg/day, Milnacipran 12.5–200 mg/day, Mirta-
zapine 15–45mg/day, Moclobemide 150–600 mg/day, Nefazodone
200–600 mg/day, Nortriptyline 75–150mg/day, Phenelzine 45–
90mg/day, Pramipexole 0.375–4.5 mg/day, Reboxetine 8–12mg/
day, Sertraline 50–200 mg/day, Trazodone 150–400 mg/day, Trimi-
pramine 75–300 mg/day, and Venlafaxine 75–375mg/day.
These target ranges were mainly deﬁned by U.S. Food and Drug
Administration (FDA)-approved labelings. However we made some
adjustments to these ranges to reﬂect clinical practice patterns that
might not have been considered in the FDA-reviewed studies accord-
ing to Gartlehner et al. (2011). In case dosing range had multiple
patterns by products, we adopted the widest range. For the drugs for
which we could not ﬁnd out dose ranges in FDA-approved labels or
Gartlehner et al. (2011), we used databases of UK Medicines and
Healthcare Products Regulatory Agency (MHRA) and the European
Medicines Agency (EMA). For amineptine, dothiepin/dosulepin, mian-
serin, nomifensine and tianepine we could not ﬁnd a standard dose
range, and we therefore accepted any dose range.
2.5. Search methods
Searches of the Cochrane Depression, Anxiety and Neurosis
Group (CCDAN) registers were conducted up to May 2012.
CCDAN's trial registers are collated from routine weekly generic
searches of MEDLINE (1950-), EMBASE (1974-) and PsycINFO
(1967-), quarterly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL) and additional databases. Reports of
trials are also sourced from international trials registers of the
World Health Organization's trials portal (ICTRP), ClinicalTrials.
gov, drug company home pages, the hand-searching of key
journals, conference proceedings and other (non-Cochrane) sys-
tematic reviews and meta-analyses. Details of CCDAN's generic
search strategies can be found on the Group's website (http://
ccdan.cochrane.org/specialised-register). (Cf. Magni et al. (2013)
and Purgato et al. (2014) for more details). We updated our search
using MEDLINE and CENTRAL in January 2015.
2.6. Data extraction and management
At least two independent review authors extracted data from
the included studies and also assessed their quality in accordance
with the Cochrane Handbook for Systematic Reviews of Interven-
tions (Higgins et al., 2011). When inadequate details of methodo-
logical characteristics of trials were provided, the authors were
contacted in order to obtain further information.
We extracted the following data from the ﬂexible dose arms in
the included studies:
1) Number of participants in each arm.
2) Mean daily dosage actually prescribed and its SD.
We graded each study's potential source of bias as high, low or
unclear in the following domains (Higgins et al., 2011; Wood et al.,
2008):
1) Allocation concealment
2) Blinding
Any disagreement was resolved by discussion of the two raters
and, where necessary, in consultation with a third author.
2.7. Statistical analysis
We conducted the analyses if, for each antidepressant drug,
there was at least one trial comparing it against either of our
standard drugs, ﬂuoxetine or paroxetine.
In the primary analysis we included all relevant studies and
calculated, for each drug, the weighted ratio of mean doses from
direct comparisons. First the ratio of the mean doses for each
study was calculated, and then it was weighted by the total sample
size to ﬁnd the weighted mean ratio. We converted paroxetine
mean doses of each study into ﬂuoxetine mean dose studies by
using the weighted ratio of mean doses from trials directly com-
paring ﬂuoxetine and paroxetine, i.e. by multiplying the mean
doses of paroxetine of each trial by this weighted mean ratio, and
then combined the paroxetine trials with the ﬂuoxetine trials.
Then the overall weighted mean ratio of each drug were recalcu-
lated to deﬁne the drug's dosage equivalent to ﬂuoxetine 40 mg/d.
If a certain antidepressant was compared both to ﬂuoxetine
and paroxetine in the same trial, in order to avoid double counting
in the synthesis of ﬂuoxetine and paroxetine datasets, we divided
the number of participants in the comparator drug arm in half.
We conducted the following four sensitivity analyses to exam-
ine the robustness of our primary analysis.
1. We conducted a meta-analysis of the ratio of means (RoM)
between a target drug and ﬂuoxetine or paroxetine, when there
were two or more trials reporting both the mean and SD for
their ﬂexible dose arms (Friedrich et al., 2008, 2012). We used
the ﬁxed effect model, as we assume that all the comparisons
should be measuring the same underlying, true ratio of means.
The results were then recalculated to deﬁne the drug's dosage
equivalent to ﬂuoxetine 40 mg/d and its 95% conﬁdence inter-
val (CI). We also calculated I-squared to examine heterogeneity
of the ratios across trials.
2. We did the same analysis as the primary but by using only the
ﬂuoxetine dataset. As we used both ﬂuoxetine and paroxetine
combined dataset in our primary analysis and the validity of
the method combining the two datasets was not certain, this
sensitivity analysis examined how the results might be differ-
ent when based on the ﬂuoxetine dataset only without addi-
tional paroxetine results.
3. Although in the included studies both the standard and
comparator drug have been titrated to be optimally effective
thanks to the ﬂexible-dose design, it does not necessarily
assure that they are equally efﬁcacious. We therefore ran a
third sensitivity analysis by adjusting the ratio of the means in
the primary analysis by the relative risk (RR) for response for
that particular comparison. The mean of these adjusted ratios,
weighted by sample size, were then recalculated to deﬁne the
drug's dosage equivalent to ﬂuoxetine 40 mg/d.
4. Dose range set for each drug in each study might affect the
result of ratio of mean dose in each study. Therefore, we
excluded outlying studies in which the comparator dose range
did not include the value calculated from our primary analysis.
Then we conducted this fourth sensitivity analysis using the
same calculation as our primary analysis.
Finally, we followed and adapted the Grading of Recommenda-
tions, Assessment, Development and Evaluation (GRADE) system
(Balshem et al., 2011), and rated the quality of evidence of our
ﬁndings, i.e., conﬁdence we can place in the equivalence estimates,
from the following three points of view in three grades of high,
moderate or low. The grading of high was downgraded if there were
signiﬁcant risks of bias in the included studies (study limitations), if
95%CI were wide from a clinical point of view and/or if there were
only a few contributing studies (imprecision), or if I-squared in the
Y. Hayasaka et al. / Journal of Affective Disorders 180 (2015) 179–184 181
ROM meta-analysis was above 50% and/or if results differed sub-
stantively in sensitivity analyses (inconsistency).
3. Results
3.1. Included studies
We found 144 ﬂexible dose trials meeting the inclusion criteria.
Of these, mean doses could be extracted from 83 studies (14 131
participants), contributing 61 comparisons for ﬂuoxetine and 24
comparisons for paroxetine. One 3-arm study comparing ﬂuox-
etine, paroxetine and sertraline was included. We treated this
study as three 2-arm (i.e. ﬂuoxetine vs. paroxetine, ﬂuoxetine vs.
sertraline, paroxetine vs. sertraline) studies and divided the
sample size of sertraline arm in half where appropriate in order
to avoid double-counting the same subjects in the evidence
synthesis. Of the 167 arms included, dose ranges set for 153 arms
(91.6%) were completely within the range deﬁned above for the
selection of studies, and those for 14 (8.4%) overlapped with, but
either the upper limit was above or the lower limit was below,
these ranges (2 for amitriptyline, 7 for imipramine, 1 for mirtaza-
pine, 1 for nortriptyline, 2 for trazodone, and 1 for venlafaxine).
We could extract SD of mean dose in 51 studies. Fig. 1 shows the
PRISMA ﬂowchart of study selection and Webappendix 1 shows
the characteristics of the included studies. We found no study of
amineptine, amisulpride, citalopram, milnacipran, nomifensine,
phenelzine, pramipexole, tianeptine, or trimipramine.
3.2. Primary analysis
In the primary analysis, mean dosage of ﬂuoxetine 40 mg/day
was equivalent to paroxetine dosage of 34.0 mg/day. Table 1 shows
the equivalent dosages of each drug compared to ﬂuoxetine
40 mg/day in the primary analysis combining both the ﬂuoxetine
and paroxetine datasets.
3.3. Sensitivity analyses
Table 1 tabulates the results from the four a priori sensitivity
analyses.
Sensitivity analysis 1 using RoM meta-analysis provide not only
equivalent dosages but also their 95%CI along with measure of
heterogeneity. Low to moderate heterogeneity was suggested for
agomelatine, desipramine, maprotiline, nefazodone, and sertraline.
In sensitivity analysis 3, RR for response of each individual RCT
was not signiﬁcant except for one study and the pooled RR for each
drug was not signiﬁcant except for sertraline (1.11, 95%CI: 1.03 to 1.20,
Webappendix 1). The results, adjusted for these signiﬁcant differ-
ences in efﬁcacy, were concordant with the primary analysis results.
Overall the results from the four sensitivity analyses were
largely concordant with those from the primary analysis. Doxepin
was the only drug for which differences greater than 20% in two or
more sensitivity analyses were noted (140.1 mg in the primary
analysis but 93.2 mg in Sensitivity analysis 1, 181.3 mg in Sensi-
tivity analysis 3 and 196.3 mg in Sensitivity analysis 4).
3.4. Quality of evidence supporting dose equivalency
Quality of evidence supporting dose equivalency for each drug
is also shown in Table 1. High quality of evidence supported dose
equivalency for agomelatine, amitriptyline, desipramine, imipra-
mine, maprotiline, moclobemide, nefazodone, paroxetine, sertra-
line and venlafaxine. The supporting evidence was judged
moderate for bupropion, clomipramine, dothiepine, doxepin, ﬂu-
voxamine, mirtazapine, reboxetine and trazodone.
4. Discussion
This is the ﬁrst study to examine dose equivalence of antidepres-
sants based on randomized evidence. We carried out a systematic
and comprehensive search for all ﬂexible-dose randomized trials
comparing either ﬂuoxetine or paroxetine, the two most extensively
studied antidepressants in the literature, against another active
antidepressant and integrated their results by calculating the mean
ratio of the achieved doses, weighted by numbers of included
patients, which was then recalculated back to be equivalent to
40 mg/day of ﬂuoxetine. The results of this primary analysis were
largely corroborated by four sensitivity analyses, except for doxepin.
The quality of supporting evidence was rated as high or moderate for
most of the examined antidepressants, except for escitalopram,
lofepramine, mianserin and nortriptyline.
There have been a few attempts at ﬁnding dose equivalency of
antidepressants. In comparison with Ali (1998) proposal, our
results tended to ﬁnd considerably lower dosages to be equivalent
to ﬂuoxetine 40 mg/day except for noritriptyline. In comparison
with Fava and Davidson (1996) study, mean dose of ﬂuvoxamine,
nefazodone, noritriptyline, paroxetine and sertraline were com-
paratively close to our results, but similar to Ali's table, other drugs
dosages were much higher than our results. It must be pointed out
that these authors did not provide sufﬁcient details about how
they calculated the equivalency and it appears that their methods
were mostly unsystematic and opinion-based.
Our study followed the method originally used for antipsychotics
by Davis (1974), who employed data from double-blind ﬂexible-dose
randomized trials of chlorpromazine and calculated the mean dose of
each antipsychotic drug that was as effective as the standard com-
parator chlorpromazine 100 mg/day. Davis's results have been used by
guidelines and textbooks for decades. Recently the same method was
applied to atypical antipsychotics (Stefan Leucht et al., 2015). As
discussed in the Introduction, there are other proposed methods to
calculate dose equivalence and no single method may be considered
the gold standard in all circumstances (Patel et al., 2013). Given the
clinical and methodological importance of deﬁning dose equivalency,
further efforts to examine this issue for antidepressants are warranted.
The results from our study and from other methods need be taken into
consideration together in discussing dose equivalency of antidepres-
sants in the future.
The present study is not without limitations. First, the number
of included studies and participants were relatively small for someFig. 1. PRISMA ﬂow chart of study selection.
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Table 1
Dose equivalent to 40 mg ﬂuoxetine.
Praimary analysisa Sensitivity analysis 1b Sensitivity analysis 2c Sensitivity analysis 3d Sensitivity analysis 4e Quality of
evidence
Number of
included
studies
(N.s.)
Number of
participants
(N.p.)
Weighted
mean dose
(/ﬂu40 mg)
N.s. N.p. Ratio of means
[95%CI]
Recalculated
mean dose
(/ﬂu40 mg)
[95%CI]
I2 (%) N.s. N.p. Weighted
mean dose
(/ﬂu40 mg)
N.s. N.p. Weighted
mean dose
(/ﬂu40 mg)
N.s. N.p. Weighted
mean dose
(/ﬂu40 mg)
Agomelatine 2 1143 53.2 2 1143 1.33 [1.29, 1.38] 53.2 [51.6, 55.2] 0 2 1143 53.2 2 1143 51.0 2 1143 53.2 high
Amineptine n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a.
Amisulpiride n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a.
Amitriptyline 8 653 122.3 4 278 3.27 [3.06, 3.49] 130.8 [122.4, 139.6] 85 6 356 99.6 6 552 137.0 5 306 106.4 high
Bupropion 2 201 348.5 2 201 9.10 [8.19, 10.12] 364.0 [327.6, 404.8] 89 1 123 402.1 1 123 346.2 2 201 348.5 moderate
Citalopram n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a.
Clomipramine 2 1073 116.1 1 1019 n.a. n.a. n.a. 1 54 102.1 1 1019 119.3 2 1073 116.1 moderate
Desipramine 2 104 196.3 2 104 4.91 [4.29, 5.62] 196.4 [171.6, 224.8] 0 2 104 196.3 1 58 187.4 2 104 196.3 high
Dothiepin 2 119 154.8 2 119 3.30 [3.06, 3.55] 132.0 [122.4, 142] 99 2 119 154.8 1 60 158.0 1 60 231.7 moderate
Doxepin 3 166 140.1 2 91 2.33 [2.02, 2.68] 93.2 [80.8, 107.2] 98 3 166 140.1 2 115 181.3 2 115 196.3 moderate
Duloxetine n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a.
Escitalopram 1 325 18.0 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. 1 325 19.0 1 325 18.0 low
Fluvoxamine 3 280 143.3 3 280 3.98 [3.66, 4.33] 159.2 [146.4, 173.2] 96 1 100 119.2 1 120 232.6 2 220 159.6 moderate
Imipramine 12 1725 137.2 8 1043 2.99 [2.88, 3.10] 119.6 [115.2, 124.0] 90 7 923 121.5 8 1003 129.1 11 1665 139.5 high
Lofepramine 1 122 250.2 1 122 n.a. n.a. n.a. n.a. n.a. n.a. 1 122 297.7 1 122 250.2 low
Maprotiline 2 117 118.0 2 117 2.87 [2.69, 3.06] 114.8 [107.6, 122.4] 0 1 46 125.0 1 71 124.0 2 117 118.0 high
Mianserin 1 65 101.1 n.a. n.a. n.a. n.a. n.a. 1 65 101.1 n.a. n.a. n.a. 1 65 101.1 low
Milnacipran n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a.
Mirtazapine 4 737 50.9 1 197 n.a. n.a. n.a. 2 265 54.6 4 737 44.1 4 737 50.9 moderate
Moclobemide 6 679 575.2 5 470 14.91 [14.16, 15.70] 596.4 [566.4, 628.0] 90 6 679 575.2 6 679 535.5 6 679 575.2 high
Nefazodone 6 532 535.2 2 165 13.52 [12.51, 14.61] 540.8 [500.4, 584.4] 0 4 286 563.9 4 445 560.9 5 458 516.5 high
Nomifensine n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a.
Nortriptyline 1 205 100.9 n.a. n.a. n.a. n.a. n.a. 1 205 100.9 1 205 105.8 1 205 100.9 low
Paroxetine 4 581 34.0 3 378 0.77 [0.73, 0.81] 30.8 [29.2, 32.4] 69 4 581 34.0 4 581 33.0 4 581 34.0 high
Phenelzine n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a.
Pramipexole n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a.
Reboxetine 3 941 11.5 1 168 n.a. n.a. n.a. 2 421 15.4 3 941 12.3 n.a. n.a. n.a. moderate
Sertraline 8 1676 98.5 6 1326 2.53 [2.43, 2.64] 101.2 [97.2, 105.6] 39 6 1227 95.5 7 1568 88.6 8 1676 98.5 high
Tianeptine n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a.
Trazodone 3 191 401.4 1 40 n.a. n.a. n.a. 2 83 325.1 3 191 421.9 1 43 386.9 moderate
Trimipramine n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a.
Venlafaxine 9 2684 149.4 5 1927 4.24 [4.12, 4.36] 169.6 [164.8, 174,4] 94 7 2468 150.1 7 2468 141.5 9 2684 149.4 high
SUM 83 14131 51 9000 60 9300 63 12338 70 12391
n.a.¼not available.
a Included all eligible studies.
b Included studies which reported mean and S.D. Meta-analysis of the ratio of means was conducted.
c Fluoxetine trials only.
d As in primary analysis but adjusted by relative risk of response of each study.
e Excluded outlying studies in which the comparator's ﬂexible dose range did not include the dosage calculated from the primary analysis.
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drugs. Unfortunately many of the identiﬁed ﬂexible-dose studies
using ﬂuoxetine and paroxetine did not report the mean doses
achieved in the ﬂexible dose arms. In addition, evenwhen they did
report the mean dose, they failed to report its SD, so that we were
unable to include some of the identiﬁed studies in the calculation
of RoM. Second, Davis's method assumes that antidepressants
have a dose response. For antidepressants, the dose response
relationships have been suggested but not clearly demonstrated
(Hansen et al., 2009). Davis's method is therefore of more
hypothesis-generating than hypothesis-conﬁrming nature. Third,
since the efﬁcacy of each drug may not be completely equal
(Cipriani et al., 2009), the method to consider intervention mean
dose as equivalent to comparator mean dose might not be
accurate. Fourth, dose range of each drug in each study varied
somewhat. However, when we conducted sensitivity analyses
3 and 4 to examine the inﬂuence of differences in treatment
efﬁcacy and range of dosage, we found no large differences
between the primary and sensitivity analyses except for doxepin.
Doxepin was the only drug to show inconsistent results, probably
because of the small number and inconsistency of the included
studies.
In summary, our ﬁndings can be useful for clinicians when
patients need to switch one antidepressant to another or add
another antidepressant by providing a target dose range to aim at.
In clinical practices, the clinicians should further take many more
factors into consideration, including age, sex, body weight, com-
plications and preferences of the patients on the one hand, and
possible adverse effects and costs on the other. For researchers our
ﬁndings would provide guidance for deciding dose ranges for fair
and accurate comparison of antidepressants. It is advised that
future ﬂexible dose studies report their achieved mean dose with
SD, so that more data can be analyzed by Davis's method. In
addition, other methods to estimate dose equivalency in antide-
pressants are warranted.
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